We are live on
!
Find out more
NI
Nextech Invest Portfolio holdings
AUM
$1.42B
1-Year Est. Return
304.47%
This Fund
S&P 500
This Quarter
Est. Return
+43.77%
1 Year Est. Return
+304.47%
3 Year Est. Return
+631.11%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.42B
AUM Growth
+$387M
(+37%)
Cap. Flow
+$40.6M
Cap. Flow
% of AUM
2.86%
Top 10 Holdings %
Top 10 Hldgs %
95.83%
Holding
18
New
2
Increased
4
Reduced
1
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CytomX Therapeutics
CTMX
|
+$22.6M |
| 2 |
ALMS
Alumis Inc
ALMS
|
+$15.6M |
| 3 |
Relay Therapeutics
RLAY
|
+$7.38M |
| 4 |
Corvus Pharmaceuticals
CRVS
|
+$7.18M |
| 5 |
enGene Therapeutics
ENGN
|
+$1.78M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MRSN
Mersana Therapeutics
MRSN
|
+$14M |
| 2 |
ARS Pharmaceuticals
SPRY
|
+$479K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Revolution Medicines
RVMD
$39.6B
| $739M | 52.02% |
7,601,087
| – | – |
|
2
Tyra Biosciences
TYRA
$1.91B
| $155M | 10.93% |
4,055,861
| – | – |
|
3
Tango Therapeutics
TNGX
$4.65B
| $152M | 10.7% |
7,266,081
| – | – |
|
4
Oric Pharmaceuticals
ORIC
$1.11B
| $90.8M | 6.39% |
7,162,637
| – | – |
|
|
ALMS
5
Alumis Inc
ALMS
$3.65B
| $78M | 5.49% |
3,540,998
+625,000
| +21% | +$15.6M |
|
|
6
Relay Therapeutics
RLAY
$4.34B
| $55M | 3.87% |
5,526,506
+825,000
| +18% | +$7.38M |
|
7
Zymeworks
ZYME
$1.78B
| $27.9M | 1.96% |
1,113,946
| – | – |
|
8
Kymera Therapeutics
KYMR
$9.52B
| $23.2M | 1.63% |
278,896
| – | – |
|
|
9
CytomX Therapeutics
CTMX
$788M
| $20.9M | 1.47% |
+4,449,932
| New | +$22.6M |
|
10
Context Therapeutics
CNTX
$55.1M
| $19.4M | 1.37% |
7,419,355
| – | – |
|
11
Cullinan Oncology
CGEM
$1.09B
| $16.2M | 1.14% |
1,141,145
| – | – |
|
|
12
enGene Therapeutics
ENGN
$122M
| $15.8M | 1.11% |
2,324,943
+200,000
| +9% | +$1.78M |
|
|
13
Corvus Pharmaceuticals
CRVS
$1.25B
| $6.58M | 0.46% |
+450,000
| New | +$7.18M |
|
14
Arvinas
ARVN
$517M
| $5.72M | 0.4% |
539,394
| – | – |
|
|
SLN
15
Silence Therapeutics
SLN
$496M
| $5.02M | 0.35% |
952,400
| – | – |
|
16
Monte Rosa Therapeutics
GLUE
$2.07B
| $5M | 0.35% |
304,237
+25,000
| +9% | +$478K |
|
|
17
ARS Pharmaceuticals
SPRY
$695M
| $4.9M | 0.35% |
610,703
-50,000
| -8% | -$479K |
|
|
MRSN
18
DELISTED
Mersana Therapeutics
MRSN
| – | – |
-482,689
| Closed | -$14M |
|
Similar funds
KCM
BC
WC
IHG
PTC
PPC
KCMH
APCM
Nextech Invest's Q1 2026 Portfolio in Review
As of Q1 2026, Nextech Invest held 18 positions worth $1.42B, up 37% from $1.03B the previous quarter. Its ten largest holdings account for 96% of the portfolio.
Nextech Invest's Q1 2026 filing shows 2 new, 4 increased, 1 reduced and 1 closed positions. Its largest new stake was CytomX Therapeutics: 4,449,932 shares worth $20.9M. The largest sale was Mersana Therapeutics, an estimated $14M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- Nextech Invest's largest Q1 2026 buy was CytomX Therapeutics: 4,449,932 shares worth $20.9M.
- Nextech Invest added most to Alumis Inc in Q1 2026, an estimated $15.6M increase.
- Nextech Invest's biggest Q1 2026 reduction was ARS Pharmaceuticals, cutting an estimated $479K.
- Nextech Invest fully exited Mersana Therapeutics in Q1 2026, selling an estimated $14M.
- Nextech Invest's ten largest holdings make up 96% of its $1.42B portfolio in Q1 2026.
- Nextech Invest opened 2 new positions and closed 1 in Q1 2026.
- Nextech Invest's portfolio value rose 37% quarter-over-quarter to $1.42B.
Based on Nextech Invest's 13F filing for Q1 2026, filed 15 May 2026.